The patient was followed up for 14 months, and the expression of each transcript (shown in Figure 1C ) demonstrated that all four transcripts of the patients showed a decreasing trend with the prolongation of the medication time, presenting a good response to flumatinib.
← all excerpts
Chronic myelogenous leukemia coexpressing V-e16a2, V-e13a2, e13a2, and e14a2 <i>BCR::ABL1</i> fusion transcripts: a case report and review of the literature.
1
—
—